Lymphoma
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
NCI-93-C-0133 (Multi-center study)
Print this page 
Investigator(s): |
Wyndham H. Wilson, M.D., Ph.D.
Principal Investigator
Phone: 301-435-2415
wilsonw@mail.nih.gov
|
|
|
|
Therese White, R.N., M.S.N.
Research Nurse
Phone: 301-402-5886
whiteth@mail.nih.gov
|
Peggy Shovlin, R.N., B.S.N.
Research Nurse
Phone: 301-594-6597
mshovlin@mail.nih.gov
|
|
| |
Primary Eligibility:
- Stage I bulky, and stage II-IV large cell lymphoma
- HIV negative
- No prior therapy
- Not pregnant or nursing
Study Outline:
- Outpatient treatment with dose-adjusted EPOCH
- Patients with CD20+/L26+ lymphomas receive rituximab on day 1 of each cycle
- Treatment repeated every 3 weeks for 6-8 courses
Additional Information:
- This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
- There is no charge for medical care received at NIH Clinical Center.
- FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
- PDQ (Physicians Data Query) - provides additional details about this study for health care providers.
Reviewed: 8/25/09
Updated: 5/14/09
Back to Top
